Royal Bank Of Canada Issues Positive Forecast for Ralliant (NYSE:RAL) Stock Price

Ralliant (NYSE:RALFree Report) had its target price hoisted by Royal Bank Of Canada from $71.00 to $73.00 in a report published on Friday morning,Benzinga reports. The brokerage currently has a sector perform rating on the stock.

RAL has been the subject of a number of other reports. Evercore initiated coverage on Ralliant in a research note on Tuesday, June 9th. They set an “outperform” rating and a $80.00 price target for the company. BMO Capital Markets initiated coverage on shares of Ralliant in a research note on Monday, July 20th. They issued a “market perform” rating and a $78.00 price objective on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Ralliant in a report on Monday, May 4th. Truist Financial restated a “buy” rating and set a $82.00 target price (up from $68.00) on shares of Ralliant in a research report on Friday. Finally, Oppenheimer upped their target price on shares of Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $75.70.

Read Our Latest Report on RAL

Ralliant Stock Performance

RAL stock opened at $65.78 on Friday. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.52 and a quick ratio of 1.05. Ralliant has a 1 year low of $37.27 and a 1 year high of $75.41. The company has a market cap of $7.36 billion and a P/E ratio of -6.06. The stock’s fifty day moving average price is $67.20 and its 200-day moving average price is $54.34.

Ralliant (NYSE:RALGet Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.63 by $0.05. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.The company had revenue of $567.80 million during the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, equities analysts forecast that Ralliant will post 2.83 earnings per share for the current year.

Ralliant Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 23rd. Investors of record on Monday, June 8th were paid a dividend of $0.05 per share. The ex-dividend date was Monday, June 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Ralliant’s payout ratio is -1.83%.

Institutional Investors Weigh In On Ralliant

A number of institutional investors have recently bought and sold shares of RAL. Danske Bank A S purchased a new stake in Ralliant in the 4th quarter worth $25,000. V Square Quantitative Management LLC purchased a new position in shares of Ralliant in the fourth quarter valued at about $26,000. Allworth Financial LP boosted its stake in shares of Ralliant by 134.4% in the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after acquiring an additional 293 shares during the period. Palisade Asset Management LLC bought a new position in shares of Ralliant in the third quarter worth about $26,000. Finally, BOKF NA purchased a new stake in shares of Ralliant during the third quarter worth about $29,000.

Ralliant News Summary

Here are the key news stories impacting Ralliant this week:

  • Positive Sentiment: Quarterly results exceeded expectations: Ralliant reported second-quarter revenue of approximately $568 million, up 13% year over year, and adjusted EPS of $0.68 versus the $0.63 consensus estimate. Adjusted net earnings were $76 million, while net earnings were $57 million. Ralliant Reports Second Quarter 2026 Results and Raises Full Year Guidance
  • Positive Sentiment: Full-year and third-quarter outlooks topped consensus: Ralliant guided third-quarter EPS to $0.72-$0.78 and revenue to $570 million-$590 million, above analyst estimates of $0.68 and $556.4 million, respectively. Full-year 2026 adjusted EPS guidance was raised to $2.76-$2.90 from an analyst consensus of $2.65, with revenue expected around $2.25 billion-$2.30 billion. Ralliant forecasts 2026 revenue and productivity savings
  • Positive Sentiment: Cost-reduction efforts could support future margins: Ralliant’s enterprise productivity program is targeting $50 million-$60 million in annualized run-rate savings by 2028, providing a potential boost to earnings and cash flow.
  • Positive Sentiment: Analysts raised targets: Citigroup increased its target to $82 and initiated a “buy” rating, Truist raised its target to $82 while reaffirming “buy,” and RBC lifted its target to $73 while maintaining a “sector perform” rating. These targets imply meaningful upside from the recent trading level. Benzinga analyst actions
  • Neutral Sentiment: Trading volatility increased: RAL experienced a temporary limit-up/limit-down trading pause during the earnings session, signaling elevated short-term volatility rather than a fundamental change in the business.
  • Negative Sentiment: Valuation and execution risks remain: Despite the adjusted earnings beat, investors may continue to focus on Ralliant’s reported profitability, integration or productivity-program execution, and the gap between the stock’s recent price and analyst targets.

About Ralliant

(Get Free Report)

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

Recommended Stories

Analyst Recommendations for Ralliant (NYSE:RAL)

Receive News & Ratings for Ralliant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ralliant and related companies with MarketBeat.com's FREE daily email newsletter.